Ten63 Therapeutics

United States - Durham, North Carolina

• 16/06/2023
• Series A
• $5,190,000

Ten63 Therapeutics is focused on improving human health by developing better, more durable therapeutics against cancer and some of the world’s most lethal diseases. We are leveraging our proprietary in silico platform BEYOND to generate novel therapeutics to hit previously undruggable targets while bringing the paradigm of durable response into early drug design through our unique ability to predict and overcome drug resistance.

We are hiring.
At Ten63, we want a better world with healthier people! We value passion, teamwork, out of the box thinking and determination to solve even what seems impossible. We embrace diversity and are committed towards inclusion. If you think you have what it takes to be a part of out team, please apply.

Related People

Marcel Frenkel, PhDFounder

United States - Raleigh-Durham-Chapel Hill Area

Driven to improve the outcomes for patients with cancer and other deadly diseases I co-founded and lead Ten63 Therapeutics. At Ten63 we have developed a novel computational platform - BEYOND. BEYOND uses molecular voxel theory (MVT), a technique developed at the Donald lab at Duke University and enhanced by Ten63's CTO Dr. Mark Hallen, to become the first systematic drug discovery platform in the world. With BEYOND we believe we can successfully develop effective and durable treatments to highly bio-medically validated, yet currently elusive targets, in order to change the paradigm of care for patients.

LinkedIn https://www.linkedin.com/in/marcelfrenkel/